Indications
Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
Composition
- Active substance
- sacituzumab govitecan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Trodelvy
- Active substance
- sacituzumab govitecan
- ATC code
- L01FX06
- Therapeutic area
- Breast Neoplasms, Triple Negative Breast Neoplasms
- Marketing authorisation holder
- Gilead Sciences Ireland UC